
Moderna and Merck Announce Positive Melanoma Vaccine Trial Results
Moderna and Merck have reported promising results from a late-stage trial of their mRNA-based cancer vaccine, showing it significantly reduced the recurrence of melanoma.
43 stories found

Moderna and Merck have reported promising results from a late-stage trial of their mRNA-based cancer vaccine, showing it significantly reduced the recurrence of melanoma.
William Blair has initiated coverage of Advanced Micro Devices (AMD) with a 'Market Perform' rating.
Chime (CHYM) has presented its strategic plans for its upcoming phase of growth during the William Blair Conference, detailing its future expansion and development initiatives.
RBC Capital has maintained its Outperform rating on Carvana (CVNA), and William Blair has kept its Outperform rating on Medline (MDLN) following a warehouse fire.
William Blair, an investment banking and asset management firm, has announced updates to its Conviction List, which typically includes its top investment recommendations.
LPL Financial is scheduled to present at the upcoming William Blair Growth Stock Conference.
Oklo's stock experienced a dip after the company announced that its first-quarter loss widened compared to the previous year. Despite the financial results, William Blair reiterated an 'Outperform' rating for the company.
William Blair has released an updated list of its conviction stocks.
Investment firm William Blair has issued an 'Outperform' rating for Enovis (ENOV), indicating a positive outlook for the company's stock.
Ramaco Resources saw its stock upgraded by Goldman Sachs following year-to-date weakness, while Kforce also gained after a William Blair upgrade based on a positive staffing demand outlook. These upgrades reflect renewed analyst confidence in the companies' prospects.
William Blair has voiced concerns regarding AvePoint's pricing model and its strategic alignment with Microsoft. The financial firm's weariness suggests potential issues with AvePoint's market position or business strategy.
Analysts at William Blair have voiced their confidence regarding the future prospects of Tenaya Therapeutics, specifically highlighting the strength of the company's product pipeline.
William Blair has maintained its 'Buy' rating for AppLovin (APP), providing an analysis of the reasons behind their continued positive outlook on the company's stock.
William Blair analysts stated that MP Materials Corp. is vital for the United States to achieve independence in its rare earth supply chain, reducing reliance on foreign sources.

William Blair has identified BJ's Restaurants as a standout stock in the restaurant sector, highlighting its strong performance and potential.
William Blair has reiterated its neutral rating on Verra Mobility (VRRM) stock, indicating no change in its investment recommendation for the company.
William Blair has highlighted The Campbell's Company's stable growth strategy, indicating a consistent approach to market expansion and financial performance.

Investment firm William Blair has issued its first rating for Campbell's Company, expressing a positive view on the company. This marks a new assessment of Campbell's market position and financial outlook.
Real is scheduled to present at the William Blair 46th Annual Growth Stock Conference, a key event for investors and companies.
Lifecore Biomedical is scheduled to participate in the 46th Annual William Blair Growth Stock Conference. The company will likely present its strategies and financial performance to investors at the event.
nLIGHT, a leading provider of high-power semiconductor lasers, has announced its participation in the upcoming William Blair 46th Annual Growth Stock Conference and the Baird 2026 conference.
William Blair has begun its coverage of Natera (NTRA) stock, assigning it an "Outperform" rating. This initiation suggests a positive long-term outlook for the company's shares.
William Blair has reaffirmed its 'Market Perform' rating for Avantor (AVTR) following the departure of the company's Chief Financial Officer. This rating reflects a neutral outlook on the stock given the recent leadership change.
William Blair has initiated coverage of Cameco with an "Outperform" rating and a $165 fair value, raising questions about whether uranium is entering a supercycle.
William Blair has downgraded its rating for Varonis Systems, Inc. (VRNS), citing concerns that AI disruption is clouding the outlook for infrastructure software.
William Blair has maintained its Outperform rating for Fidelity National Information Services (FIS), indicating continued positive sentiment towards the company's stock.
PagerDuty's stock was downgraded by William Blair following a disappointing financial quarter and weak guidance.
William Blair has downgraded its stock rating for LegalZoom, citing uncertainty in search performance as a key factor in the decision.
William Blair has begun its coverage of Zura Bio (ZURA) with an "Outperform" rating, indicating a positive outlook on the company's stock performance.

William Blair has updated its Conviction List, adding Oracle, ServiceTitan, Everpure, and Dynatrace. This revision reflects changes in the firm's top investment recommendations.
Wise Group PLC has issued a response to an inquiry regarding its business operations, as William Blair maintains a positive long-term outlook for the company.
William Blair has begun coverage of Insulet with an Outperform rating, stating that the current valuation gap for the company is difficult to justify.
Resmed has announced its participation in the 46th Annual William Blair Growth Stock Conference, as reported by The Globe and Mail.
Investment bank William Blair has announced its acquisition of Inner Circle, a sports M&A bank, aiming to bolster its dealmaking capabilities within the sports industry.
William Blair has started coverage on McKesson (MCK) with an Outperform rating, citing the company's durable competitive moat.
William Blair has initiated coverage on pharmaceutical distributor Cardinal Health, assigning it an "Outperform" rating and questioning if the company is a "stealth compounder."
William Blair has downgraded Adobe (ADBE) to 'Market Perform' and lowered its price target, reflecting a revised outlook on the software company's stock.
Adobe is experiencing increasing downgrades and analyst caution, with a William Blair analyst citing various reasons to steer clear of the stock, despite acknowledging that AI may not necessarily devastate the company's business.
William Blair has reaffirmed its 'Buy' rating on Microsoft (MSFT) stock, providing reasons for its continued positive outlook on the technology giant, as discussions continue regarding whether the stock is a buy.
Centrus Energy Corp. (LEU) plans a $560 million expansion at its Oak Ridge facility for uranium enrichment, with William Blair reaffirming an Outperform rating.